

Title Immunoglobulin Treatments

Reference Number: RDF2029-23

Date of Response: 21/11/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

In the past 3 months [latest 3 months available] how many patients have received the following immunoglobulin treatments [for any disease]?

| Treatment | Trust total |
|---------------------------------|-------------|
| Cutaquig | 0 |
| Cuvitru | 0 |
| Gammanorm | 0 |
| Gammagard | 0 |
| Hizentra | 0 |
| Hyqvia | 0 |
| Intratect | *<5 |
| Iqymune | 10 |
| Kiovig | 11 |
| Privigen | 20 |
| Octagam | *<5 |
| Panzyga | *<5 |
| Subgam | 0 |
| Any other normal immunoglobulin | 7 |

*<5 - **Section 40 (2)** Please note:

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases, ≤5 is used to indicate that a figure between 1 and 5 is being suppressed. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.

The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.